
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity is in a good position to benefit from the growing demand for digital health solutions, as evidenced by their strong customer engagement and sales activity. The AI search product is a significant contributor to their forward outlook, which is expected to drive incremental budget opportunities and improve customer interactions through upsell activity. The "No Harm" study has solidified Doximity's market leading reputation among health systems and providers, and their AI search product is fueling a diverse AI pipeline, particularly with the Insights product, which offers significant momentum and value for pharmaceutical companies. Doximity's strong financials and conservative posture towards AI monetization, as well as their successful implementation of the same playbook in monetizing telehealth, makes them a strong contender in the digital health space.
Bears say
Doximity is facing challenges in the competitive market, with slowing growth in both expansion and top customer metrics. The company is also facing a declining number of pharmaceuticals under patent, potentially reducing its revenue opportunity in the marketing solutions segment. Additionally, the company's increased investment in AI compute, engineering, and marketing is leading to compressed margins, and there are limited near-term catalysts for growth. These factors, coupled with a lower growth outlook for FY27, contribute to the negative outlook on Doximity's stock.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares